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Apathy is pervasive across many neuropsychiatric disorders but is poorly characterized
mechanistically, so targeted therapeutic interventions remain elusive. A key impediment
has been the lack of validated assessment tools to facilitate translation of promising
findings between preclinical disease models and patients. Apathy is a common symptom
in Huntington’s disease. Due to its established genetic basis and the availability of
defined animal models, this disease offers a robust translational framework for linking
motivated behavior with underlying neurobiology and an ideal context in which to evaluate
a quantitative, translational apathy assessment method. In this study we therefore aimed
to demonstrate the validity of using touchscreen-delivered progressive ratio tasks to
mirror apathy assessment in Huntington’s disease patients and a representative mouse
model. To do this we evaluated Huntington’s disease patients (n = 23) and age-matched
healthy controls (n = 20), and male R6/1 mice (n = 23) and wildtype controls (n =
29) for apathy-like behavior using touchscreen-delivered progressive ratio tasks. The
primary outcome measure of the assessment was breakpoint, defined as the highest
number of touchscreen responses emitted before task engagement ceased. Patients and
R6/1 mice were both found to exhibit significantly reduced breakpoints relative to their
respective control groups, consistent with apathy-like behavior. This performance was
also not associated with motoric differences in either species. These data demonstrate
the utility of touchscreen-delivered progressive ratio tasks in detecting clinically relevant
motivational deficits in Huntington’s disease. This approach may offer a platform from
which clinically relevant mechanistic insights concerning motivation symptoms can be
derived and provide an effective route for translation of promising preclinical findings into
viable therapeutic interventions.
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INTRODUCTION
Apathy is a multidimensional construct that encompasses a
wide range of clinical features, including reductions in goal-
directed behavior, cognitive activity, and emotional expression
(1–4). It is a prominent feature of many neurodegenerative
and neuropsychiatric disorders including Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease (HD),
and schizophrenia (5–8).
Huntington’s disease is classically conceptualized with a
triadic presentation of motoric, cognitive, and neuropsychiatric
symptoms (9). Apathy is one of the earliest neuropsychiatric
symptoms (10) with prevalence rates of 34–76% across the
disease course (11–13) and can present in advance of the
motoric symptoms associated with the disease (14). Unlike other
neuropsychiatric features of HD, apathy progressively worsens as
the disease advances (10, 15) and is associated with a broader
decline in other cognitive domains and daily functioning (16).
Despite its prevalence and impact on quality of life for both
patients and caregivers, apathy remains a difficult symptom
to treat effectively in HD, with no successful HD apathy
treatment trial reported to date (17). This is partly due to
the often mixed neuropsychiatric presentation of these patients
and concerns around polypharmacy particularly related to
medication interactions and side-effects leading to exacerbation
of other neuropsychiatric symptoms (14, 18). Beyond these
clinical practice-related concerns, effective treatment of apathy is
also considered challenging as it is linked to a range of etiologies
involving multiple neural systems (19) such that underlying
causal mechanisms remain unknown. Indeed, distinct from
other neuropsychiatric symptoms associated with HD, apathy
has not yet been associated with physiological biomarkers such
as plasma cytokines (20) or white matter fractional anisotropy
(21), potentially indicating a multi-factorial pathophysiological
cascade, though a recent study did report an association with
changes in cortical CB1R expression (22). Furthermore, objective
measures for apathy, which are needed to detect and monitor
symptom severity and track the effectiveness of interventions, are
lacking. Therefore, identification of viable neuropharmacological
targets and screening of prospective treatments for efficacy is
particularly challenging.
A substantial proportion of apathy-targeted research has
utilized subjective questionnaire assessments. Questionnaires are
problematic for longitudinal tracking of symptoms and for
clinical trials, as they rely on the accuracy of patient self-report
or require an observant and unbiased informant, with some
indications that the extent of correlation between reports of
neuropsychiatric symptomology in HD from patients relative to
informants varies as a function of disease state, suggesting issues
related to patient insight can impact severity estimates (23, 24).
Furthermore, variability in the approach used to evaluate apathy
in HD has been suggested as a contributor to the wide prevalence
rate estimates for this symptom (14). To advance understanding
of apathy in HD and generate efficacious treatment strategies,
there is therefore a pressing need to develop more objective
motivation assessments that can ideally be used both preclinically
and in patients (25).
Touchscreen-delivered motivation assessments could offer a
route to achieve this goal (26–29). Performance in touchscreen
assessments targeting other cognitive domains in humans
(30, 31) and rodents (32–34) are similarly impacted by
mutations in a homologous disease related gene (Dlg2) (35),
and in Alzheimer’s disease patients and the 3xTgAD rodent
model of the disease (36). Findings derived from these tools
therefore have the potential to facilitate rapid identification of
relevant neurobiological substrates, pathological mechanisms,
and novel therapeutics.
We have capitalized on this approach to assess motivational
deficits inHDusing analogous touchscreen-delivered progressive
ratio (PR) tasks in patients and in a well-characterized transgenic
mouse model of this disease. In PR schedules, participants earn
a reward following emission of a defined number of responses.
The number of responses required for each subsequent reward
increases according to a pre-defined sequence. This continues
until the participant reaches their breakpoint, which is defined as
the number of responses emitted for the last reward successfully
earned before responding ceases (37). Breakpoint is taken as
an index of the reinforcing effects of a stimulus (38) and is
based on an effort-cost computation where reward value is
weighed against effort expenditure (39). A PR schedule can
therefore measure specific sub-processes of motivated behavior,
namely reward sensitivity and sustaining effort. These schedules
have been widely used in animals and humans to evaluate
the reinforcing effects of drugs and the impact of varying
dosages (40, 41). More recently, however, their utility in
measuring motivation in neuropsychiatric conditions has been
demonstrated in schizophrenia, where breakpoints have been
related to clinical amotivation as assessed by behavioral scales
(39, 42) and in relevant animal disease models (43, 44).
Here, we utilized a newly developed touchscreen-based PR
task to objectively assess motivation in HD patients (31). This
task is largely non-verbal and the associated cognitive demands
are low, making it suitable for use in a range of clinical
conditions. In parallel, we employed the rodent touchscreen PR
schedule (45, 46) to evaluate motivation in the R6/1 mouse
model. In addition to numerous similarities in paradigm design
and implementation, these assessments provide a variety of
analogous outcome measures thereby facilitating direct inter-
species comparison of performance metrics. Taken together, this
study presents an initial characterization of the touchscreen PR
schedule as a tool with utility in HD populations and with high
translational potential for the assessment of motivation in this
disease context.
MATERIALS AND METHODS
Human Participant Case Selection
Huntington’s disease patients (n = 23) were recruited from
the regional NHS Huntington’s disease service clinic at the
John van Geest Center for Brain Repair, Cambridge, UK.
All had received a diagnostic confidence rating of 4 by an
accredited HD clinician. Of these, 20 were receiving HD
treatment (either monotherapy with olanzapine, amantadine,
tetrabenazine or risperidone; or combinations of these) and
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TABLE 1 | Demographic and clinical characteristics of human participants.
Demographic/clinical
characteristic
HD Control p-value
N 23 20 –
Sex (M:F) 13:10 10:10 –
Age 53.6 (25–76; 14.6) 52.2 (20–81; 20.2) n.s.
MMSE (max. 30) 26.0 (19–30; 3.0) 29.7 (28–30; .63) ***
ACE-R (max. 100) 77.6 (56–93; 12.9) 97.2 (96–99; 1.7) ***
CBI-R (max. 180) 53.1 (13–114; 23.7)
Total motor score 28.0 (4–50; 13.9)
Functional activity 18.0 (11–25; 4.3)
Total functional
capacity
8.7 (3–25; 4.8)
Mean (range; standard deviation). n.s., non-significant; ***p < 0.001. MMSE, Mini-
Mental State Examination; ACE-R, Addenbrooke’s Cognitive Examination-Revised; CBI-R,
Cambridge Behavioral Inventory-Revised.
13 were also treated for affective problems (with selective
serotonin reuptake inhibitors or benzodiazepine monotherapy,
or a combination thereof).
Patients were evaluated using the UHDRS and scores
for total functional capacity and functional activity scales as
well as total motor scores were recorded. The Addenbrooke’s
Cognitive Examination-Revised [ACE-R; (47)] was administered
as a measure of general cognition and the Cambridge
Behavioral Inventory-Revised [CBI-R; (48)] was used to evaluate
behavioral symptoms.
Age-matched controls (n = 20) were recruited from a
volunteer panel at the Behavioral and Clinical Neuroscience
Institute, University of Cambridge, UK. Exclusion criteria for
controls were presence of known neurological or psychiatric
disorders, use of psychoactive medications or significant head
injury. Older controls (over 50 years) were screened for cognitive
impairment using the ACE-R with the established cut-off of 88 or
above (47).
The human arm of the study was approved by the local
Research Ethics Committee (reference number 09/H0308/2)
and Cambridge University Hospitals NHS Foundation Trust
Research and Development Department. All participants
provided informed consent in accordance with the Declaration
of Helsinki. See Table 1 for demographic details and
clinical characteristics.
Apathy Questionnaire Assessment
An informant-rated version of the Apathy Evaluation Scale
(AES) (49) was employed as a clinical apathy measure in the
HD patients. The AES assesses behavioral and psychological
manifestations of apathy over the past 4 weeks and item
frequency is scored on a four-point scale. AES scores are reported
as a percentage, with higher values indicating increased levels
of apathy.
Controls completed a self-rated apathy questionnaire
(LARS-e). Based on the Lille Apathy Rating Scale (LARS)
(50), the LARS-e is modified and extended to be sensitive to
motivational variations in healthy populations (51). Items are
rated on a five-point scale. LARS-e scores are reported as their
reciprocal percentage, with higher scores indicating increased
levels of apathy.
Human Progressive Ratio Task
This task is part of the EMOTICOM battery (31) and is
administered on a touchscreen laptop (Dell XT3). A maximum
of 437 trials are possible in this task, each being self-paced with
participants required to press a “Next” button to begin each
trial. The task has three consecutive trial blocks associated with
a progressively smaller reward value (£1, 20p, and 4p).
In each trial, four red squares are presented and participants
are instructed to select the square that differs in size to the
other three. Participants initially need to complete 4 selections
to receive a reward, with this doubling to 8, 16, and 32 responses.
Participants are informed that they can stop performing the task
at any point, but they must then sit facing the screen for any
remaining session time. The task is stopped by pressing a “Quit”
button, which remains available throughout. Participants were
not rewarded with money in this study as performance-based
reimbursement was not permitted by the ethics committee, but
they were instructed to engage as if real money was at stake.
Breakpoint was defined as the number of trials completed
before quitting the task. Other outcome measures included
the post reinforcement pause, defined as the average time
taken to initiate the next trial following a rewarded trial,
and the running rate, defined as the number of responses
emitted per second over the task correcting for the post
reinforcement pause (i.e., responses/total time in seconds minus
post reinforcement pauses).
Animals
Male R6/1 mice (52) on the B6CBAF1/J background bred
at the University of Cambridge were utilized in this study.
R6/1 (n = 23; mean CAG repeat length = 120 ± 0.29) and
wildtype (WT) littermate controls (n= 29) were moved from the
breeding facility at 6 weeks of age and housed in the behavioral
assessment facility in mixed genotype groups in a humidity-
and temperature-controlled housing room with a 12 h light-
dark cycle (lights off: 0700). Mice were left undisturbed except
for normal husbandry for 7 days following transfer to allow
facility acclimatization. Cages were changed once weekly and
drinking water bottles twice weekly. All animals experienced
single daily behavioral training sessions 5–7 days per week with
experimenters blind to genotype. All procedures were conducted
during the dark phase of the cycle, reviewed and approved by the
University of Cambridge AWERB and performed in accordance
with the United Kingdom Animals (Scientific Procedures) Act
(1986) and the United Kingdom Animals (Scientific Procedures)
Act (1986) Amendment Regulations 2012.
Food Restriction and Reward Habituation
From 7 weeks of age, animals were regularly handled to habituate
them to the experimenters and weighed daily to establish
stable free-feeding weights. Food restriction to ∼85–90% of
free-feeding weight consisted of providing limited amounts of
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standard laboratory chow (RM 3; Special Diet Services, Essex,
UK) daily.
Animals were habituated to the liquid reward used in
the PR assessment (Yazoo Strawberry UHT milkshake;
FrieslandCampina UK, Horsham, UK), by placing a sample in
a small bowl in each cage for two consecutive days immediately
prior to behavioral training. The liquid reward sample was
provided coincident with chow pellet delivery to minimize
neophobia (32).
Apparatus
Behavioral assessments were conducted in standard Bussey-
Saksida mouse touchscreen chambers (Campden Instruments
Ltd., Loughborough, UK) as described in detail previously (32–
34). Briefly, these chambers consist of a behavioral arena with a
perforated stainless steel floor and trapezoidal black plastic walls
which open on to a touchscreen (12.1 inch; resolution 800 ×
600). In these chambers, an array of infrared (IR) photo-detection
beams are projected immediately above the surface of the
touchscreen so that animals do not have to exert any mechanical
pressure to successfully register a response. A reward collection
magazine is located on the wall opposite the touchscreen. This
contains an LED which is illuminated upon reward delivery.
Each arena is housed within a dense fibreboard sound
attenuating chamber equipped with an LED house light and a
fan to provide ventilation and mask background noise. Animals
are observed through overhead IR-sensitive cameras and IR
emitters sited along the length of the arena. The chambers are
also equipped with IR photo-detection beams which run across
the floor of the arena (rear beam = 3 cm from magazine port
and front beam = 6 cm from screen) to monitor horizontal
locomotor activity independently of task-specific locomotor
proxy measures. A tone generator and speaker are also located
directly above the behavioral arena.
For this study the standard “5-choice” mask (Campden
Instruments Ltd.) was placed in front of the touchscreen (45, 46).
This mask contains a row of 5 square apertures measuring 4 ×
4 cm, each spaced 1 cm apart and positioned 1.5 cm above the
floor of the arena. The mask was used to guide responding and
minimize unintended screen contact by the mice. The central
response aperture was the only location in which stimuli were
presented in this study.
Touchscreen Behavioral Chamber Training
Mice were first habituated to the chambers and then underwent
initial operant training to associate stimulus offset with
reward delivery in the magazine unit positioned opposite the
touchscreen. A fixed ratio (FR) schedule requiring an invariant
number of touchscreen responses to yield reward delivery was
then introduced. Reward volume was set at 20 µL throughout.
Behavioral Chamber Habituation
Mice were habituated to the chambers with a single 20min
session in which the animals were placed in the chambers and
locomotor beam breaks, magazine entries, and screen touches
were recorded. There were no programmed consequences for any
behavioral response. To facilitate habituation, 200 µL of liquid
reward was delivered to the magazine at the start of the session.
Initial Operant Training
Initial operant training consisted of one 60min session in
which animals were trained to associate stimulus offset with
reward delivery. This session consisted of 30 trials in which the
target stimulus (a white square) was presented in the central
touchscreen response aperture. The stimulus was displayed for
30 s and upon stimulus offset a tone (3 kHz, 1,000ms) was
presented, the magazine illuminated and liquid reward (20 µL)
delivered. The magazine remained illuminated until reward
collection, at which point a 5 s inter-trial interval (ITI) was
enforced. Upon completion of the ITI the next trial began with
stimulus display. If during presentation the animal touched the
target stimulus, it was immediately removed from the screen,
the tone was presented, the magazine was illuminated and a
triple volume of liquid reward (60 µL) was delivered. Mice
were required to collect 30 rewards in a single session before
progression to the next stage of training.
Fixed Ratio Training
Animals were then introduced to the fixed ratio (FR) contingency
as described previously (46). Initially this consisted of a single
session of FR 1 training in which the white square stimulus was
presented in the central touchscreen response aperture until the
animal made a response in that location. Responding resulted
in stimulus removal, tone presentation, magazine illumination
and reward delivery (20 µL). Animals were given 12 trials of
this contingency with a maximum session time of 60min and a
4.5 s ITI.
The day after successful completion of 12 FR 1 trials, animals
progressed to the FR 2 schedule. This was identical to the FR
1 schedule except that two screen touches were required for
each reward delivery. In this schedule, the first screen touch
resulted in brief (500ms) removal of the target stimulus and
delivery of a “chirp” tone (3 kHz, 10ms) to indicate that a
response had been successfully registered. The second screen
touch had the same consequences as in the FR 1 schedule.
Animals were required to complete 6 FR 2 trials (thereby
emitting the same total number of responses as in the FR 1
schedule) to successfully complete this training phase. Upon
completion of FR 2 training, animals were moved to the FR
3 schedule in which three responses were required for each
reward delivery. The other parameters of this program were
identical to the FR 2 schedule, except that animals were required
to complete 4 trials under this contingency to standardize the
total number of responses emitted in each FR training phase
to 12.
Upon completion of FR contingency training and to ensure
performance stability, animals were given a further seven
consecutive sessions of the FR 3 schedule. The parameters of
these sessions were identical to those used previously, except
that the maximum number of trials permitted was increased to
8 to ensure responding was sustainable. Upon completion of
these sessions, animals were rested for up to 3 days to allow
any mice delayed in training to successfully reach the necessary
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performance criteria. All animals were then given two further 8
trial sessions of the FR 3 schedule and permitted to progress to
the PR assessment upon completion of 8 trials in a single session.
This training protocol resulted in one R6/1 animal being delayed
by a single session.
Progressive Ratio Assessment
PR assessment was conducted as previously reported (45, 46).
The schedule parameters used were identical to those established
in the FR contingency training, except that upon successful
completion of a trial the subsequent response requirement for
reward delivery was increased on a linear +2 basis (i.e., a PR
2 schedule requiring 1, 3, 5, 7, 9 responses, etc.). To minimize
differential reward exposure, a limit of 45 trials was applied
in these sessions. An inactivity timeout was also enforced that
specified if an animal did not make a screen response after 5min
of stimulus display or make a magazine entry within 5min of
reward delivery, the behavioral session ended and the mouse was
removed from the chamber.
Breakpoint was operationally defined as the number of
responses emitted to obtain the last reward before inactivity
time out or session completion. The total number of screen
responses was also analyzed to enable assessment of responses
emitted beyond those required for the last successfully completed
trial. Response rate was calculated via conversion of the inter-
reinforcer interval to rate per trial (53–55). Rates for individual
subjects were fitted with a negative exponential function y = a−bx
where y represents response rate, a represents y intercept, –b
represents decay, and x represents trials (44, 55, 56). The intercept
(a) and decay (–b) parameters were then extracted and tested for
between-group statistical significance.
Animals were given three consecutive PR 2 sessions and the
mean performance of each animal was used for analysis. PR
data were collected when the animals were 11 weeks of age to
ensure that the well-characterized age-dependent impairment in
motor output in this strain (52) did not confound any observed
differences in task performance.
Locomotor Activity Assessment
The locomotor capabilities of the animals used in this study were
also evaluated on the same day as the final PR assessment session.
For this assessment the touchscreen chambers were converted
to the “autoshaping” configuration (32, 57) to provide a distinct
context for the animals. In this configuration the magazine was
moved to a central location directly in front of the touchscreen
and the five aperture mask was replaced with a two aperture
version with one aperture on either side of the magazine. To
further enhance the contextual difference, the houselight was
illuminated during this assessment. In this evaluation, mice
were placed in the chambers for 10min and in that time the
number of locomotor activity beam breaks, magazine entries and
screen touches was recorded. This provides a proxy assessment of
locomotor activity based on the exploration of a relatively novel
environment and should not be confounded by factors related to
the PR assessment. It therefore provides a reliable evaluation of
motoric capabilities.
Statistical Analyses
Analyses were conducted using the open-source statistical
environment R (58). Variables were checked for normality using
the Shapiro-Wilk test. For the human participants, data were
compared usingMann-WhitneyU-tests. Cohen’s d effect size was
computed for all comparisons. Correlations were analyzed using
Spearman rank coefficients. For the rodent data, Welch’s two
sample t-tests were applied. Unless otherwise indicated, data are
presented as mean± standard error of the mean. The Bonferroni
correction for multiple comparisons was applied as necessary,
and all analyses are two-tailed at an α level of 0.05.
RESULTS
Huntington’s Disease Patients Show
Reduced Motivation on the Touchscreen
PR Task
Patients demonstrated a significantly reduced breakpoint value
relative to controls (Control mean: 312.9 ± 146.4 (SD); Patient
mean: 110.4 ± 111.8 (SD); U = 394.0, p < 0.001, d = 1.6)
(Figure 1A). Running rate was also significantly reduced in the
patient group (Control: 0.5 ± 0.1 responses per second; Patient:
0.2 ± 0.1 responses per second; U = 17.0, p < 0.001, d = 2.2).
Post reinforcement pause was significantly elevated in patients
(Control: 0.95 ± 0.42 s; Patient: 2.6 ± 1.2 s; U = 56.0, p < 0.001,
d = 1.4).
Breakpoints in the patient group were highly correlated with
their total functional capacity, a global indicator of functional
decline in everyday activities with lower scores indicating more
severe impairment (r = 0.45, p < 0.05), but not with their
UHDRS total motor scores (r = −0.37, p = 0.09). Furthermore,
neither total functional capacity or UHDRS total motor scores
were significantly correlated with the post reinforcement pause
or running rate (p values> 0.17).
Questionnaire-Derived Apathy Levels
Correlate With PR Performance
The mean control group apathy score using LARS-e was 27.9 ±
7.2%. The mean apathy score in the patient group using AES
was 61.9± 15.3%. A significant negative correlation was detected
between apathy questionnaire score (higher indicating greater
apathy) and PR breakpoint value across the groups (r = −0.52,
p < 0.001) (Figure 1B), suggesting that higher levels of everyday
apathy were associated with reduced motivation in the PR task.
R6/1 Transgenic Mice Exhibit Reduced
Motivation in the Touchscreen PR
Assessment at 11 Weeks of Age
R6/1mice were significantly lessmotivated to obtain the palatable
strawberry milkshake reward relative to wildtype littermates as
assessed by breakpoint [mean WT breakpoint: 19.92 ± 1.38;
mean R6/1 breakpoint: 12.94 ± 1.00; t(48.162) = 4.0879; p <
0.001; d = 1.09; Figure 2A] and total screen touches [mean WT
total touches: 134.78 ± 16.63; mean R6/1 total touches: 65.28
± 7.94; t(39.603) = 3.7714; p < 0.001; d = 0.97; Figure 2B].
Post reinforcement pause was also significantly elevated in the
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FIGURE 1 | Human progressive ratio breakpoint and correlation with questionnaire apathy scores. (A) Average breakpoint for controls and HD patients; ***p < 0.001.
(B) Levels of questionnaire-determined apathy for controls and patients (LARS-e and AES) correlate with progressive ratio breakpoint.
R6/1 animals relative to WT [mean WT PRP: 13.73 ± 1.07;
mean R6/1 PRP: 27.84 ± 2.56; t(29.606) = −5.0861; p < 0.001;
d =−1.53; Figure 2C].
R6/1 Transgenic Mice Exhibit Reduced
Maximal Operant Output in Touchscreen
PR
Comparison of the estimated peak PR response rate, which
represents the projected maximum possible rate of touchscreen
responding, indicated a significant reduction in R6/1 animals
relative to wildtype littermates, consistent with a lower intrinsic
motivational baseline [WT: 22.76 ± 1.08; R6/1: 12.45 ± 1.03;
t(45.687) = 6.892; p < 0.001; d = 1.96; Figure 2D]. In contrast,
comparison of the response decay rate, which represents the
decline in the rate of touchscreen responding across the PR
session, revealed no significant effect of genotype [WT: 0.20
± 0.014; R6/1: 0.25 ± 0.037; t(26.075) = −1.159; p = 0.2568;
Figures 2E,F].
Touchscreen PR Performance Was Not
Confounded by Generalized Locomotor
Disturbance or Body Weight Changes in
R6/1 Mice
R6/1 touchscreen PR performance was assessed at 11 weeks of
age which is ∼4 weeks prior to the onset of any reported motor
deficits in this HD model (52). To confirm the absence of any
potentially confounding motoric deficits, the locomotor activity
of the animals was assessed in a novel configuration of the
touchscreen chamber.
No significant differences were detected between R6/1 and
WT littermates across several measures including the number
of infrared beam breaks across the chamber floor adjacent to
the reward magazine [WT: 26.69 ± 2.27; R6/1: 26.68 ± 3.01;
t(41.715) = −0.0569; p = 0.9549], the number of infrared beam
breaks across the floor of the chamber adjacent to the left side of
the touchscreen [WT: 80.31 ± 5.28; R6/1: 94.05 ± 9.55; t(33.475)
= 1.2585; p = 0.2169], the number of infrared beam breaks
across the floor of the chamber adjacent to the right side of the
touchscreen [WT: 79.93 ± 7.50; R6/1: 75.82 ± 7.29; t(48.358) =
−0.39318; p = 0.6959], the number of ambulatory transitions
from the touchscreen to the magazine [WT: 16.28 ± 1.19; R6/1:
14.32 ± 1.33; t(45.944) = −1.0941; p = 0.2796], the number of
touches recorded on the left side of the touchscreen [WT: 55.14±
3.52; R6/1: 51.77± 3.95; t(45.899) =−0.63641; p= 0.5277] and the
number of touches recorded on the right side of the touchscreen
[WT: 49.24 ± 3.68; R6/1: 56.77 ± 5.82; t(36.74) = 1.0932; p =
0.2814]. A numerical but non-significant increase in the number
of magazine entries made by the R6/1 animals was detected [WT:
9.86± 1.35; R6/1: 19.82± 4.90; t(24.2) = 1.9605; p= 0.06155].
Age-dependent changes in body weight have also been
reported in the R6/1 mice (52) and as this PR assessment was
based on the collection of a palatable strawberry milkshake
reward it was important to exclude this factor as a contributor
to the observed performance impairment. Comparison of body
weight during the PR assessment, when expressed as the mean
(WT: 22.95 ± 0.33g; R6/1: 22.54 ± 0.42 g; p = 0.4459) or as the
mean percentage of free feeding weight (WT: 89.03± 0.90; R6/1:
87.64 ± 0.67; p = 0.2213), revealed no significant differences
between the genotypes.
DISCUSSION
In this study, we have demonstrated the potential of a fully
quantitative, touchscreen-delivered motivational assessment to
detect apathy-like behavior in HD patients and a well-
characterized rodent disease model.
Specifically, we have shown that manifest HD patients exhibit
lower breakpoints relative to healthy controls in a touchscreen PR
assessment. Critically, task performance was related to everyday
levels of apathy as determined by behavioral questionnaires, but
not motor scores. Using an analogous rodent touchscreen PR
assessment, we found that the R6/1 transgenic HD mouse model
exhibited lower breakpoints relative to wildtype littermates in the
absence of any generalized locomotor disturbance.
Our finding of increased apathy in patients on an established
questionnaire is consistent with previous studies (7, 10, 13). The
extent of apathy on such scales has been related to reduced quality
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FIGURE 2 | Progressive ratio performance in R6/1 and wildtype mice. Rodent progressive ratio performance: (A) breakpoint; (B) total screen touches; (C)
post-reinforcement pause; (D) predicted peak performance; and (E,F) decay rate. WT, wildtype; R6/1, HD model; *p < 0.05; ***p < 0.001; ns, non-significant.
of life (59), highlighting the importance of apathy as a therapeutic
target. The correlation between PR breakpoint and the AES we
identified suggests that touchscreen PR may provide an effective
approach to objectively measure apathy in HD. On the basis
that apathy severity can be quantitated using this approach,
touchscreen PR may ultimately be a useful tool to objectively
assess motivation deficits in future studies that can inform the
mechanistic basis of apathy and serve as an outcome measure in
interventional studies.
Our patient group comprised a convenience sample of
individuals attending our HD clinic, and therefore represents a
wide range of disease stages. The degree of patient engagement
with the task that we observed here highlights the potential
for the touchscreen PR platform to be used for longitudinal
motivational assessment of patients across the whole disease
course. It will be important in future work to further validate
the task in cohorts at discrete disease stages to determine its
sensitivity to detect motivational deficits, particularly in the
prodromal phase when such deficits may be subtle. Following
such prodromal patients longitudinally using the touchscreen PR
platform represents a further important future validation study,
as does appropriate evaluation of test-retest reliability.
Given that our patient cohort was a convenience sample,
a wide range of different pharmacotherapies was represented.
That touchscreen PR was able to detect a motivational
impairment emphasizes the point that current HD treatment
approaches are unable to effectively ameliorate the apathy
associated with this condition (10, 14, 17). However, the
pharmacotherapeutic heterogeneity in the sample, coupled
with concerns around medications used in HD potentially
exacerbating neuropsychiatric symptom severity (14) means we
cannot rule out the possibility that the magnitude of apathy
detected in some of the patients here may have been enhanced by
their medication profile. In order to fully disentangle the relative
contributions of medication and pathophysiology to the level of
motivation quantitated by touchscreen PR in HD, assessment of
cohorts with uniform pharmacotherapeutic profiles or cohorts in
which medication is temporarily suspended will be necessary in
future studies.
The impaired PR performance exhibited by the R6/1 mice,
ahead of any motor deficits, further increases the face and
construct validity of these animals as a means to explore HD
motivational deficits (60). Impairments in motivation to earn
reward have been reported in other HD rodent models including
the BAC HD, z_Q175 KI and Hdh mouse strains (61–65)
and the BACHD rat (66–68). Given that the R6/1 mouse is
widely studied, particularly with respect to novel therapeutics,
it offers a powerful platform, in combination with the PR task,
to deliver novel insights into the pathophysiological mechanisms
underlying this early onset HD symptom and to evaluate
potential therapeutic avenues.
The striking consistency between the human and rodent PR
data observed here complements findings in touchscreen studies
targeting other cognitive domains involving humans and mice
carrying mutations in a schizophrenia-related gene (35, 69)
and in Alzheimer’s patients and a rodent disease model (26,
36). Our findings establish the utility of this approach in the
context of Huntington’s disease. As such, touchscreen PR may
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ultimately facilitate apathy-targeted therapeutic translation in
HD by standardizing the assessment and output measures used
to evaluate motivation in both patient and model systems.
A challenge of evaluating motivation using effort expenditure
tasks in movement disorder patients and corresponding rodent
models is the potential for confounding due to generalized
motor slowing and motor impairment. While the reduced
breakpoint observed in patients here was accompanied by
reduced running rate and increased post reinforcement pause,
PR task performance was not significantly correlated with clinical
assessment scores of motor function. These results suggest that
gross motoric deficits are unlikely to account for the observed
PR deficits.
Similarly, the R6/1 model is known to develop significant
motoric dysfunction (52) which could likewise contribute to
PR performance deficits. However, when general locomotor
activity was assessed, no significant impairments were observed.
Consistent with the patient data, R6/1 mice also exhibited a
significantly increased post-reinforcement pause—a parameter
that typically is associated with changes in motivational state
as opposed to locomotor activity (70, 71). Indeed, given this
absence of a motoric impairment in the transgenic animals,
the significant reduction in estimated peak response rate in
the R6/1 group observed here is therefore consistent with a
lower intrinsic motivational baseline in these animals (55).
Taken together, these observations indicate that the profound
impairment in PR performance detected in the R6/1 animals was
not due to motor impairment but rather represents a genuine
motivational deficit.
In this study, we have demonstrated the utility of the
touchscreen PR paradigm in a representative clinical sample of
HD and detected the expression of an apathy-like phenotype
in a well-characterized rodent model of the disease. Future
studies employing this approach are now required to measure
apathy at different disease stages in both clinical and pre-
clinical contexts. More broadly, the findings reported here
highlight the potential for the touchscreen PR schedule to
provide an important platform upon which to investigate
the neurobiological underpinnings of disrupted motivation
and to evaluate novel interventions intended to ameliorate
such disruptions across a range of neurodegenerative and
neuropsychiatric disorders. These findings also indicate the
capacity for the touchscreen PR schedule to be leveraged
for either forward or reverse translational studies in
this area.
However, these conclusions should be tempered by noting
the assessment of a convenience patient sample here, which
represents heterogenous disease state and pharmacotherapeutic
administration profiles. Similarly, while this study contributes
crucial further evidence of the cross-species translational
capabilities of touchscreen delivered cognitive assessments (26,
35, 36, 69) the considerable degree of face validity between the
human and non-human touchscreen assessments achieved here
does not, in the absence of further validation, guarantee the
presence of similar levels of construct and predictive validity.
Efforts to evaluate construct and predictive validity are advancing
for a range of touchscreen tasks (72, 73) and given the long
history of PR schedules in studies of non-human species (37, 74)
and the resulting substantial evidence base covering the effects
of a range of manipulations on performance, combined with the
recent implementation of PR schedules in humans (31, 74), such
validation studies for PR are now eminently feasible. Indeed,
with these considerations in mind, an important development
will therefore be to apply this translational paradigm in a cohort
of premanifest individuals who are not yet exhibiting the motor
signs of HD. Such a group would more closely reflect the
early stage deficits we have shown in the 11 week old R6/1
mice here.
Taken together, we have established the utility of touchscreen
PR as an approach for the objective, fully quantitative assessment
of motivation inHD. To develop apathy-targeted therapeutics for
HD and other neuropsychiatric disorders, it will be necessary to
identify the specific sub-processes of motivated behavior that are
disrupted as well as the underlying circuitry and neurochemical
alterations. It follows that sound translational models in which
putative therapeutics can be evaluated will be essential for
progress in this area. The cross-species validated touchscreen PR
paradigm, as a proxy measure for apathy, has the potential to
address these needs and ultimately support improved treatments
for this symptom in Huntington’s disease and other disorders.
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